In April 2014 it was annnounced that GnuBIO Inc had been acquired by Bio-Rad Laboratories for an undisclosed sum. GnuBIO, Inc worked in the scalable DNA sequencing technology space for the Diagnostic and Applied Markets. Utilizing its proprietary microfluidic and emulsion technologies, Grounded in emulsion and microfluidic technology developed at Harvard University. GnuBIO worked within these markets to develop nucleic acid analysis based systems that scale as function of both patient sample and genomic region. The GnuBIO system has the capability of running numbers of samples that are in line with diagnostic and applied market endeavors for a cost that represents orders of magnitude less than current technology. The same system also has the headroom to compete in the high throughput market, and will achieve a comparable output, in hours, to what the leading technology takes weeks to produce.
